PARP inhibitors (PARPis) induce synthetic lethality in BC patients carrying loss-of-function mutations in breast cancer susceptibility gene 1 (BRCA1) and BRCA2 and are routinely used in the clinical treatment of metastatic BC [229]. This evidence concerns the gene BRCA2 and breast cancer.